Smith Group Asset Management’s Teva Pharmaceutical Industries Limited TEVA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2016
Q2
– Sell
-3,344
Closed -$179K – 511
2016
Q1
$179K Sell
3,344
-100
-3% -$5.87K 0.01% 241
2015
Q4
$226K Hold
3,444
– – 0.01% 224
2015
Q3
$194K Hold
3,444
– – 0.01% 224
2015
Q2
$204K Sell
3,444
-890
-21% -$54.9K 0.01% 216
2015
Q1
$270K Hold
4,334
– – 0.01% 257
2014
Q4
$249K Sell
4,334
-208
-5% -$11.6K 0.01% 259
2014
Q3
$244K Buy
4,542
+208
+5% +$11K 0.01% 217
2014
Q2
$227K Buy
+4,334
New +$222K 0.01% 225

Other funds holding TEVA

Smith Group Asset Management's TEVA Position: Q2 2016 in Review

Smith Group Asset Management sold out of Teva Pharmaceutical Industries Limited (TEVA) in Q2 2016, closing a stake of 3,344 shares — an estimated $179K sold.

Smith Group Asset Management first reported a position in TEVA in Q2 2014 and held it in 8 quarters. The position peaked at $270K in Q1 2015. 813 funds tracked by Wall St. Rank hold TEVA as of Q2 2016.

  • Smith Group Asset Management reported no remaining Teva Pharmaceutical Industries Limited position as of Q2 2016 after selling out during the quarter.
  • Smith Group Asset Management sold 3,344 Teva Pharmaceutical Industries Limited shares in Q2 2016, an estimated $179K.
  • Smith Group Asset Management first reported a position in Teva Pharmaceutical Industries Limited in Q2 2014 and held it in 8 quarters.
  • Smith Group Asset Management's Teva Pharmaceutical Industries Limited position peaked at $270K in Q1 2015.
  • 813 funds tracked by Wall St. Rank held Teva Pharmaceutical Industries Limited as of Q2 2016.

Based on Smith Group Asset Management's 13F filing for Q2 2016, filed 26 Jul 2016.